市場調查報告書
商品編碼
1468502
中性粒細胞減少症治療市場報告(按治療方法(集落刺激因子、抗生素、抗真菌藥物、抗病毒藥物)、配銷通路(醫院藥房、零售藥房、線上藥房)和地區)2024-2032 年Neutropenia Treatment Market Report by Treatment (Colony-Stimulating Factors, Antibiotics, Antifungals, Antivirals), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032 |
2023年,全球IMARC Group中性白血球減少症治療市場規模達153億美元。雲端平台的日益普及、智慧型手機銷售的不斷上升以及廣泛的研發 (R&D) 活動是推動市場發展的一些關鍵因素。
中性粒細胞減少症是一種以幫助身體抵抗感染的白血球 (WBC) 計數異常低為特徵的疾病。它是由各種情況或疾病引起的,包括感染、化療、先天性骨髓異常、自體免疫疾病和某些藥物(藥物引起的中性粒細胞減少症)。嗜中性球是在骨髓中產生的,骨髓是較大骨骼(如椎骨、肋骨和骨盆)中的海綿組織。中性粒細胞減少症的治療包括抗生素、抗真菌和抗病毒藥物,透過消滅攻擊身體的有害真菌、酵母和細菌來幫助對抗感染。這些藥物有助於降低感染的可能性並刺激骨髓產生更多的白血球。
對中性粒細胞減少症和化療相關副作用的認知不斷提高是推動市場成長的關鍵因素之一。與此一致,對膠囊和片劑形式且給藥途徑方便的口服藥物的需求不斷成長,有利於市場成長。此外,主要參與者積極傳播有關中性粒細胞減少症的預防措施、早期診斷和有效治療的相關資訊和知識,這反過來又推動了市場的成長。此外,群眾對可用治療替代方案的認知不斷增強,這是另一個促進成長的因素。除此之外,製造商還專注於推出具有成本效益的中性粒細胞減少症治療藥物,這正在促進市場成長。此外,利用新型藥物傳遞方法有助於提高患者的便利性,進而提高患者的依從性,對市場成長產生正面影響。除此之外,發燒性中性粒細胞減少症藥物的增加以及促進和生產生物學名藥的新立法的實施正在為市場創造積極的前景。該市場的另一個推動力是透過線上零售入口網站(例如註冊網站)輕鬆獲得藥物,這提供了以實惠的價格訂購和購買藥物的便利性。其他因素,包括廣泛的研發(R&D)活動、創新和有效藥物的推出、癌症發病率上升、由於基礎設施改善而更容易獲得醫療保健設施、消費者支出能力不斷增強以及政府實施各種促進癌症發展的舉措公共衛生,預計將推動市場成長。
The global neutropenia treatment market size reached US$ 15.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 23.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032. The increasing adoption of cloud platforms, escalating sales of smartphones and extensive research and development (R&D) activities represent some of the key factors driving the market.
Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast, and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.
The rising awareness of neutropenia and chemotherapy-related side effects is one of the key factors driving the market growth. In line with this, the increasing demand for oral drugs that are available in capsule and tablet form and consist of convenient routes of administration is favoring the market growth. Moreover, key players are actively engaged in disseminating relevant information and knowledge regarding preventive measures, early diagnosis, and effective treatment of neutropenia, which, in turn, is propelling the market growth. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is acting as another growth-inducing factor. In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market. The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global neutropenia treatment market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on treatment and distribution channel.
Colony-Stimulating Factors
Antibiotics
Antifungals
Antivirals
The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the treatment. This includes colony-stimulating factors, antibiotics, antifungals and antivirals. According to the report, colony-stimulating factors represented the largest segment.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the distribution channel. This includes hospital, retail, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for neutropenia treatment. Some of the factors driving the North America neutropenia treatment market included increasing demand for internet-enabled services by enterprises, extensive research and development (R&D) activities, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global neutropenia treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.